JVJaroslav Vaňásek

Jaroslav Vaňásek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaroslav Vaňásek has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Bohuslav Melichar

    Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Zdravotníků 248/7, 779 00, Olomouc 9, Czech Republic

    2 shared publications
  • Denisa Pohanková

    Department of Oncology and Radiotherapy, University Teaching Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic

    2 shared publications
  • Filip Ďatelinka

    Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic

    2 shared publications
  • Igor Sirák

    Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, Hradec Králové, Czech Republic

    2 shared publications
  • Iveta Kolářová

    Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

    2 shared publications
  • Jiří Petera

    Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic

    2 shared publications

Latest Publications

  • Open Access

    The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer

    by Iveta Kolářová, Bohuslav Melichar, Igor Sirák, Jaroslav Vaňásek, Jiří Petera, Kateřina Horáčková, Denisa Pohanková, Filip Ďatelinka, Zuzana Šinkorová, Milan Vošmik

    The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with four or more positive lymph nodes or extracapsular extension, regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than three positive lymph nodes should be treated with radiotherapy, there is controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in cases of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.


  • Open Access

    The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer

    by Iveta Kolářová, Bohuslav Melichar, Igor Sirák, Jaroslav Vaňásek, Jiří Petera, Kateřina Horáčková, Denisa Pohanková, Filip Ďatelinka, Zuzana Šinkorová, Milan Vošmik

    The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with 4 or more positive lymph nodes or extracapsular extension regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than 3 positive lymph nodes should be treated with radiotherapy, there is a controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in case of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.